Immunic (NASDAQ:IMUX) Receives Buy Rating from D. Boral Capital

Immunic (NASDAQ:IMUX)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $17.00 price objective on the stock.

Several other brokerages have also issued reports on IMUX. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research note on Monday, February 10th. HC Wainwright initiated coverage on Immunic in a research note on Monday, November 25th. They issued a “buy” rating and a $10.00 target price for the company. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $12.67.

Immunic Stock Up 12.4 %

Shares of NASDAQ IMUX traded up $0.13 during mid-day trading on Thursday, reaching $1.18. 1,811,698 shares of the company were exchanged, compared to its average volume of 972,905. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11. The company’s 50 day moving average price is $1.02 and its 200 day moving average price is $1.26. The stock has a market capitalization of $106.29 million, a PE ratio of -0.96 and a beta of 1.87.

Hedge Funds Weigh In On Immunic

Large investors have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the period. State Street Corp grew its holdings in Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after acquiring an additional 11,642 shares during the last quarter. Jane Street Group LLC increased its position in shares of Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after acquiring an additional 38,553 shares during the period. Virtu Financial LLC bought a new position in shares of Immunic during the third quarter valued at about $50,000. Finally, HB Wealth Management LLC bought a new position in shares of Immunic during the fourth quarter valued at about $81,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.